DIABETIC
EYE DISEASE:
YOU CAN MAKE A DIFFERENCE IN DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA
Through early detection, monitoring, and
timely referral, Doctors of Optometry can play a pivotal role in managing Diabetic Retinopathy
(DR) and Diabetic Macular Edema (DME)1-3
The information provided in this site is intended for U.S. Doctors of Optometry.
Diabetic Retinopathy and Diabetic Macular Edema Can Put Your Patients at Risk for Vision Loss.
Learn More
Diabetes Can Put People at Risk of DR and DME
- DR can impact ≈1 out of 3 adults over age 40 with diabetes4
- About half of people with DR will develop DME5
- Risk of DME increases with the severity of DR6
That is why it is critical to act! If you see or suspect DR and/or DME2,3:
EDUCATE
your patients about living with DR and/or DME and potential treatment options
REFER
appropriate DR and DME patients for timely intervention
FOLLOW UP
to ensure patients have visited a retina specialist
MONITOR
your patients with DR and/or DME
Early Action Can be Important to DR and DME Patients.
See Why
The more you know about the emerging clinical science of anti-VEGF and other potential therapies for DR and DME, the better you can help inform your patients about how treatment may be able to help.
Learn About a Treatment Option That May Be Able to Help Patients With Diabetic Retinopathy or Diabetic Macular Edema
Find Out More
Our Commitment to You
Regeneron is committed to helping you partner with your patients for comprehensive
care of DR and DME, as well as for care of certain other retinal diseases.
Important Safety Information and Indications
CONTRAINDICATIONS
- EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
WARNINGS AND PRECAUTIONS
- Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
- Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
- There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA compared with 1.5% (9 out of 595) in patients treated with ranibizumab; through 96 weeks, the incidence was 3.3% (60 out of 1824) in the EYLEA group compared with 3.2% (19 out of 595) in the ranibizumab group. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.
ADVERSE REACTIONS
- Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
- The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
INDICATIONS
EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
Please see the full Prescribing Information for EYLEA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
The information provided in this site is intended for U.S. Doctors of Optometry.
